PTJA07 Pharmaceutical Joint Assessment Now Available – ustekinumab for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response with, lost response to or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies.
This is the pharmaceutical Joint Assessment PTJA07 – on ustekinumab for the treatment of ulcerative colitis (UC). In September 2019, EMA approved the extension of
EUnetHTA started an “Error reporting and correction” procedure on 04/05/2020. The reported error was not classified as an error by EUnetHTA and the Assessment Team,
EUnetHTA is pleased to announce the publication of the second iteration of the EPL. As part of the overarching Topic Identitication, Selection and Prioritisation (TISP)
The public consultation of the draft methodological guideline “Practical considerations when critically assessing economic evaluations” is OPEN (deadline Oct. 11, 2019)
We are pleased to announce that, as of today, the draft methodological guideline “Practical considerations when critically assessing economic evaluations”, produced within WP6 B2, has
Public consultation on the guideline ”Process of information retrieval for systematic reviews and health technology assessments on clinical effectiveness” in August/September 2019
The methodological guideline ”Process of information retrieval for systematic reviews and health technology assessments on clinical effectiveness” is currently under revision by IQWiG, NIPHNO and
Reminder: Open Call for Patient Input – Joint Assessment on a medicinal product for neovascular (wet) age-related macular degeneration (AMD).
This is a friendly reminder that EUnetHTA recently started a new Joint Assessment on a medicinal product for neovascular (wet) age-related macular degeneration (AMD). To
We are pleased to announce that the final assessment for OTCA15 “Irreversible electroporation in liver and pancreatic cancer”, together with the input from external experts
EUnetHTA is pleased to announced that the document on “Patient Input in Relative Effectiveness Assessments” is now available. The document describes the process regarding direct